InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（0 笔）
内部人交易记录
首席执行官已披露买入
2
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-3.7%
基于 2 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Browse the full record of transactions filed by Southwell David P, 首席执行官. Director active across 3 companies, notably TScan Therapeutics, Inc.. Aggregated, 18 disclosures have been recorded. Breakdown: 2 buys · 0 sell. Total volume traded: €133k. Activity tracked since 8 September 2021. The latest transaction was disclosed on 3 August 2026 (J). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Southwell David P
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报18 总计
150,000 股0Common StockSEC:0001140361-26-031471:0
22,862 股0Common StockSEC:0001140361-26-027677:0
4,000 股0Common StockSEC:0001251553-26-000002:0
12,000 股@ US$30.8639.7% 占其流量Common StockSEC:0001415889-25-024280:0
30,000 股0Common StockSEC:0001140361-25-026404:0
4,000 股0Common StockSEC:0001415889-25-001027:0
113,124 股0Common StockSEC:0001140361-24-026884:0
1,650 股0Common StockSEC:0001415889-24-012891:0
70,000 股@ US$4.342100.0% 占其流量Common StockSEC:0001140361-24-020127:0
4,000 股0Common StockSEC:0001415889-24-004121:0
11,429 股@ US$18.0139.2% 占其流量Common StockSEC:0001415889-23-006696:0
2,571 股@ US$18.018.8% 占其流量Common StockSEC:0001415889-23-005991:0
10,000 股@ US$27.0552.0% 占其流量Common StockSEC:0001415889-23-005565:0
4,000 股0Common StockSEC:0001415889-23-000669:0
15,000 股@ US$3.622623.8% 占其流量Voting Common StockSEC:0000899243-22-019018:0
标准退出：2022年8月16日 (T+90)
3,200 股0Common StockSEC:0001179110-22-000384:0
48,670 股@ US$1.9738.9% 占其流量Voting Common StockSEC:0000899243-21-049764:0
11,000 股@ US$8.733337.3% 占其流量Voting Common StockSEC:0000899243-21-035442:0
标准退出：2021年12月7日 (T+90)
18 条申报中的 18 条
About Southwell David P
David P. Southwell is Chief Executive Officer and a declarant linked to PTC Therapeutics, INC., Rocket Pharmaceuticals, INC. and TScan Therapeutics, Inc., where he is also a Director at the first two companies and Chief Executive Officer at TScan Therapeutics, Inc. He has made 17 filings in total, and across the recent sample of 17 filings, buys total EUR 133167 and sells total EUR 0, between 2021-09-09 and 2026-07-06. The recent top filings include EUR 316438.4512789986 at PTC Therapeutics, INC. on 2025-09-11, EUR 283345.0316664139 at Rocket Pharmaceuticals, INC. on 2024-04-16, and EUR 250299.0651834529 at PTC Therapeutics, INC. on 2023-03-29.
